This is an open-label, phase 2 study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in 307 pancreatic cancer patients in three groups: olaparib for BRCAness (arm A), and randomization of durvalumab plus selumetinib (MEK inhibitor) [144] (arm B) or FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy (arm C) for those with KRAS mutation and negative of BRCAness. Here, KRAS is linked to pancreatic neoplasm.